CLINUVEL (ASX:CUV) Completes Phase III Vitiligo Trial Recruitment
CLINUVEL (ASX:CUV) completes recruitment for its Phase III vitiligo trial, with initial results expected in the second half of 2026.
Category: ASX-CUV
CLINUVEL Pharmaceuticals Limited
CLINUVEL (ASX:CUV) Renews Share Buy-Back Program
CLINUVEL (ASX:CUV) renews its share buy-back program for up to 1.5 million shares over the next 12 months.
Clinuvel (ASX:CUV) Announces Positive Preliminary Stroke Study Results
CLINUVEL (ASX:CUV) reports positive preliminary results from its latest stroke treatment study, highlighting high patient improvement rates.